BACKGROUND: Liver ischemia reperfusion (I/R) injury is associated with profound arginine depletion due to arginase release from injured hepatocytes. Nitric oxide (NO), shown to have protective effects in I/R, is produced by nitric oxide synthase (NOS) from the substrate arginine. The purpose of this study was to determine if nor-NOHA, a novel arginase inhibitor, would be able to increase circulating arginine levels and decrease hepatic damage following warm I/R. METHODS: C57BL/6 mice underwent partial liver warm I/R and were treated intraperitoneally with either nor-NOHA (100mg/kg) or saline. Serum and tissue samples were collected to measure liver enzyme levels, amino acids, and inflammatory mediators. The agent nor-NOHA (100mg/kg) was administered 15 min before ischemia and immediately after reperfusion. Serum amino acid analysis was performed using HPLC. RESULTS: Arginase activity after hepatic I/R peaked at 3-6h after reperfusion and resulted in a 10-fold drop in circulating arginine levels. Treatment with nor-NOHA inhibited arginase activity and reversed the arginine depletion after I/R while simultaneously increasing serum nitric oxide. In addition, circulating citrulline, a product of NOS activity, was increased in nor-NOHA-treated animals compared to controls. Inhibition of arginase also resulted in protection from hepatic I/R-induced damage in association with markedly lower hepatic TNF, IL-6, and inducible NOS mRNA levels compared to controls. CONCLUSION: Arginase blockade represents a potentially novel strategy to combat liver injury under conditions of arginine deficiency. This protection may be mediated through the arginine-NO pathway.
BACKGROUND:Liver ischemia reperfusion (I/R) injury is associated with profound arginine depletion due to arginase release from injured hepatocytes. Nitric oxide (NO), shown to have protective effects in I/R, is produced by nitric oxide synthase (NOS) from the substrate arginine. The purpose of this study was to determine if nor-NOHA, a novel arginase inhibitor, would be able to increase circulating arginine levels and decrease hepatic damage following warm I/R. METHODS: C57BL/6 mice underwent partial liver warm I/R and were treated intraperitoneally with either nor-NOHA (100mg/kg) or saline. Serum and tissue samples were collected to measure liver enzyme levels, amino acids, and inflammatory mediators. The agent nor-NOHA (100mg/kg) was administered 15 min before ischemia and immediately after reperfusion. Serum amino acid analysis was performed using HPLC. RESULTS: Arginase activity after hepatic I/R peaked at 3-6h after reperfusion and resulted in a 10-fold drop in circulating arginine levels. Treatment with nor-NOHA inhibited arginase activity and reversed the arginine depletion after I/R while simultaneously increasing serum nitric oxide. In addition, circulating citrulline, a product of NOS activity, was increased in nor-NOHA-treated animals compared to controls. Inhibition of arginase also resulted in protection from hepatic I/R-induced damage in association with markedly lower hepatic TNF, IL-6, and inducible NOS mRNA levels compared to controls. CONCLUSION: Arginase blockade represents a potentially novel strategy to combat liver injury under conditions of arginine deficiency. This protection may be mediated through the arginine-NO pathway.
Authors: Beverley A Moore; Leo E Otterbein; Andreas Türler; Augustine M K Choi; Anthony J Bauer Journal: Gastroenterology Date: 2003-02 Impact factor: 22.682
Authors: Marcel C G van de Poll; Sebastiaan J P Hanssen; Maaike Berbée; Nicolaas E P Deutz; Diethard Monbaliu; Wim A Buurman; Cornelis H C Dejong Journal: Clin Sci (Lond) Date: 2008-02 Impact factor: 6.124
Authors: Alia Shatanawi; Tahira Lemtalsi; Lin Yao; Chintan Patel; Ruth B Caldwell; R William Caldwell Journal: Eur J Pharmacol Date: 2014-10-30 Impact factor: 4.432
Authors: Wesley M Raup-Konsavage; Ting Gao; Timothy K Cooper; Sidney M Morris; W Brian Reeves; Alaa S Awad Journal: Am J Physiol Renal Physiol Date: 2017-05-17
Authors: Guoyao Wu; Fuller W Bazer; Teresa A Davis; Sung Woo Kim; Peng Li; J Marc Rhoads; M Carey Satterfield; Stephen B Smith; Thomas E Spencer; Yulong Yin Journal: Amino Acids Date: 2008-11-23 Impact factor: 3.520
Authors: Ahmet Fikret Yucel; Ahmet Pergel; Ibrahim Aydin; Hasan Alacam; Ilhan Karabicak; Tugrul Kesicioglu; Levent Tumkaya; Yildiray Kalkan; Ender Ozer; Zakir Arslan; Ibrahim Sehitoglu; Dursun Ali Sahin Journal: Int J Clin Exp Med Date: 2015-11-15
Authors: Jennifer M Bratt; Lisa M Franzi; Angela L Linderholm; Erin M O'Roark; Nicholas J Kenyon; Jerold A Last Journal: Toxicol Appl Pharmacol Date: 2009-10-02 Impact factor: 4.219